The round was led by EFI Lake Geneva Ventures, with participation from existing shareholders Start Angels Network Switzerland, Zürcher Kantonalbank, Verve Ventures, Interconsult, Club degli Investitori, Excellis Holding, and other business angels. Additionally, Hylomorph secured CHF 2.4 million in non-dilutive funds through the Innosuisse Swiss Accelerator Grant program to support patients undergoing implant surgery.
This significant funding marks a major milestone for Hylomorph as it continues pursuing its mission to make a substantial impact on patients’ care. The investment will help the Zurich-based ETH spin-off Hylomorph expand its product portfolio, as well as achieve regulatory approvals and market launch for its first indication in cardiology. In particular, the Swiss Accelerator funding will support the company’s clinical development program, to test safety and efficacy in a large group of patients suffering Cardiac Rhythm Management disorders.
“We are thrilled to have successfully closed this financing round, with EFI Lake Geneva Venture leading the investment, and to be awarded the competitive Swiss Accelerator grant. With this capital injection, we will provide patients with multiple solutions for the prevention of post-complications. Our first commitment is to patients requiring device therapy to treat arrhythmia or cardiac arrests, where we have experienced great momentum with the clinical and industrial community. We are also exploring new indications in neurostimulation as well as the integration of therapeutic agents, to increase the benefits and well-being of our patients” said Simone Bottan, CEO and co-founder at Hylomorph.
READ MORE: Microplate Dx raises £2.5m to develop rapid antibiotic test
Hylomorph participated in Venture Kick (2016) and Venture Leaders Technology (2015).
“Venture Leaders has been a unique program to put my business development on the front burner. I returned with a ton of great contacts a much clearer vision of how to run my company and an understanding of the US market. A must-have if your ambition is to build a winning business,” said Simone Bottan, CEO of Hylomorph. “The new funding will carry us to market clearance for the US and EU. Our work aims at paving a future where postoperative complications in medical implants are tamed and suppressed, combining benefits in patients’ quality of life, clinician quality of care, and healthcare cost efficiency. Our goal is in sight,” continued Simone, regarding Hylomorph’s Venture Kick Stage 3 win.
HYLOMORPH AG:Anti-fibrotic solutions for medical implants
HYLOMORPH commercialises a platform technology for the solution of the problem of fibrotic encapsulation in implantable medical devices. Fibrotic encapsulation threatens patients quality-of-life as… Read more
